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Abstract Rats bearing the Yoshida AH-130 ascites hepatoma
showed an increased expression of both uncoupling protein-2
(UCP2) (194%) and UCP3 (189%) mRNA levels in skeletal
muscle 7 days after tumour inoculation. Interestingly, an even
greater increase was observed in mRNA for both UCP2 (278%)
and UCP3 (797%) in the pair-fed animals, suggesting that the
increase in gene expression was the result of the anorexia
associated with tumour burden. The results constitute the first
report of UCP2 and UCP3 gene expression during cancer
cachexia and agree to their possible role in the increase of energy
expenditure associated with tumour growth.
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1. Introduction
Until very recently, the uncoupling protein-1 (UCP1),
present only in brown adipose tissue, was considered to be
the only mitochondrial protein carrier that stimulated heat
production by dissipating the proton gradient generated dur-
ing respiration across the inner mitochondrial membrane and
therefore uncoupling respiration from ATP synthesis. Re-
cently, two new proteins sharing a similar fuction, UCP2
and UCP3, have been described. While UCP2 is expressed
ubiquitously [1,2], UCP3 is expressed abundantly and domi-
nantly in skeletal muscle in humans [3^5] and also in brown
(BAT) and white (WAT) adipose tissues and heart of rodents
[6]. Concerning the regulation of their expression, UCP2
mRNA levels are upregulated in WAT and skeletal muscle
in obesity-resistant mice but not in an obesity-prone strain
[7], therefore suggesting a possible role as a defense mecha-
nism against high-fat induced obesity. Fasting increases UCP2
mRNA in skeletal muscle [8] while it does not seem to a¡ect
the expression of the gene in BAT. In skeletal muscle UCP3
gene expression is also modulated by food intake: its expres-
sion is increased by fasting [9].
Malignant neoplasms frequently induce a progressive loss
of lean body mass in the host associated with marked alter-
ations in the endocrine and metabolic homeostasis. The skel-
etal muscle, which accounts for almost half of the whole body
protein mass, is severely a¡ected in cancer cachexia [10^12]
and evidence has been provided for muscle protein waste as
being associated with enhanced turnover rates [13,14]. Since
cachexia tends to develop at a rather advanced stage of the
neoplastic growth, preventing muscle waste in cancer patients
is of a great potential clinical interest. Previous studies (See
[15] for review) have shown that during cachectic states there
is an increase in BAT thermogenesis both in humans [16] and
experimental animals [17]. In addition, Roe et al. [18] have
shown that there is an increased oxygen consumption in leu-
kaemic rats. It is therefore interesting to study if tumour bur-
den results in an enhanced UCP2 and UCP3 activation.
The rat ascites hepatoma Yoshida AH-130 is a suitable
model system to study the mechanisms involved in the estab-
lishment of cachexia. Its growth causes in the host rapid and
progressive loss of body weight and tissue waste, particularly
in skeletal muscle. Acceleration of tissue protein breakdown
accounts for most of the waste in the AH-130 bearers [19^21].
Detectable plasma levels of tumour necrosis factor-K (TNF)
and perturbations in the hormonal homeostasis [20] likely
play an important role in forcing the metabolic balance to-
wards the catabolic side.
We decided to investigate if pathophysiological states where
the levels of TNF are increased (such as tumour growth)
resulted in an increased expression of both UCP2 and
UCP3. Bearing this in mind, and taking into account that
skeletal muscle wasting is one of the main factors contributing
to cancer cachexia, the aim of the present investigation was to
see if tumour burden resulted in the induction of the UCP2 or
UCP3 genes in this tissue.
2. Materials and methods
2.1. Animals, tumour inoculation and treatment
Male Wistar rats (Interfauna, Barcelona, Spain) weighing about 100
g were used. The animals were maintained on a regular light-dark
cycle (light on from 08.00 a.m. to 08.00 p.m.) and had free access
to food and water. The diet (Panlab, Barcelona, Spain) consisted of
54% carbohydrate, 17% protein and 5% fat (the residue was non-
digestible material); the food intake was measured daily. Rats were
divided into three groups, namely controls, pair-fed and tumour hosts.
Pair-fed were non-tumour bearing animals which were o¡ered the
same amount of food as that eaten by the tumour bearers the previous
day. The latter received an intraperitoneal inoculum of 108 AH-130
Yoshida ascites hepatoma cells obtained from exponential tumours
(for details see [19]).
On days 0, 2, 4, and 7 after tumour transplantation animals were
weighed and anesthetised with diethyl ether. The tumour was har-
vested from the peritoneal cavity, its volume and cellularity evaluated,
and cells separated from the ascitic £uid by centrifugation at 100Ug
for 10 min. Tissues were rapidly excised, weighed, and frozen in liquid
nitrogen.
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2.2. Chemicals
All chemicals were either obtained from Boehringer-Mannheim
(Barcelona, Spain) or from Sigma (St. Louis, MO, USA).
2.3. UCP2 and UCP3 gene expression
Total RNA from gastrocnemius muscle was extracted using the acid
guanidinium isothiocyanate/phenol/chloroform method [22]. RNA
samples (20 Wg) were denaturated, subject to 1.2% agarose gel elec-
tophoresis and transferred to Hybond H membranes (Amersham).
RNA was ¢xed to membranes by illuminating with UV for 4 min.
Prehybridisation was done in a phosphate bu¡er (250 mM, pH 6.8)
containing 7% SDS, 1 mM EDTA and 1% BSA, during 1 h at 65‡C.
Membranes were hybridised in the same bu¡er with appropiate
probes (approx. 28 Bq/ng) at 65‡C for 18 h. Non-speci¢cally bound
probe was removed by successive washes in 2USSC+0.1% SDS
(10 min at 65‡C) and 1USSC+0.1% SDS (10 min at 65‡C) and
0.1USSC+0.1% SDS (15 min at 65‡C, twice). Speci¢c hybridisa-
tion was then detected by autoradiography in BioMax ¢lm (Kodak)
using intensi¢er screens during 18^48 h and quanti¢ed by densitom-
etry.
Radiolabeled probes were prepared by the random priming method
(Boehringer-Mannheim). The probes used were the entire coding
frame for mouse UCP2 [1], a cDNA clone containing the entire cod-
ing frame for mouse UCP3 (D.S. Fleury, C.F. Bouillard, GenBank
accession number AF032902), and an actine probe used as hybrid-
isation/quanti¢cation standard.
2.4. Statistical analysis
Statistical analysis of the data was performed by means of the
Student’s t-test.
3. Results and discussion
At day 2 after tumour inoculation, the food intake of the
tumour-bearing animals was not decreased (in relation with
the non-tumour-bearing controls) but it was signi¢cantly low-
er at days 4 (11%) and 7 (48%) (Table 1). Since fasting has
been demonstrated to increase both UCP2 and UCP3
mRNAs in di¡erent tissues [8], we decided to include pair-
fed animals which were given the same amount of food as
the tumour-bearing ones.
At day 7, both pair-fed and tumour-bearing animals
showed a considerable degree of body weight loss; while the
control animals increased their body weight by 33.5 þ 2.43 g,
the pair-fed group showed a signi¢cant decrease (9.72 þ 1.69 g,
PG0.01) and the tumour-bearing group showed an even greater
loss (28.9 þ 3.26 g, PG0.01). This decrease in body weight was
accompanied by a decrease in adipose weight loss a¡ecting
both WAT and BAT as we have previously described
[23,24]. Tumour burden resulted in an important decrease in
gastrocnemius weight (21%) (Table 1). EDL, soleus and tibia-
lis weights were decreased to a similar extent in the tumour-
bearing animals but also in the pair-fed group, suggesting that
the main factor involved in the muscle waste is the anorexia
induced by tumour growth.
At day 2 following tumour inoculation there were no
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Table 1
Food intake and body and muscle weights
Control Pair-fed Tumour-bearing
Food intake (g) 117 þ 6 61.3 þ 3 60.6 þ 2
Initial body weight (g) 143 þ 3 143 þ 3 153 þ 3
Final body weight (g) 176 þ 4 169 þ 4 114 þ 4
Muscle weights (mg)
Gastrocnemius 633 þ 24.6 566 þ 16.3 499 þ 23.2**
EDL 53.3 þ 0.55 46.3 þ 1.24** 39.6 þ 1.69***
Soleus 53.2 þ 1.44 43.3 þ 1.93*** 38.9 þ 2.23**
Tibialis 200 þ 3.99 176 þ 3.55** 151 þ 6.62**
Adipose tissue weights (mg)
White fat lumbar pads 705 þ 17.4 296 þ 37.4** 269 þ 44.9**
Brown interscapular 151 þ 18.4 72.2 þ 1.88** 75.8 þ 6.62**
Tumour cell content (cellsU106) ^ ^ 68.8 þ 3.74
Data are expressed as means þ S.E.M. for ¢ve animals in each group. Data correspond to day 7 after tumour inoculation. Tissue weights are
expressed as percentages of initial body weight. Statistical signi¢cance of the di¡erences (Student’s t-test): *P6 0.05, **P6 0.01, ***P6 0.001.
Fig. 1. Northern blots of gastrocnemius muscle extracts from control, pair-fed and tumour-bearing rats. Expression of both UCP2 and UCP3
mRNAs in skeletal gastrocnemius muscles was detected after hybridisation with cDNA probes (see Section 2). Autoradiographs were subjected
to scanning densitometry. td: tumour-bearing rats (days 2, 4 and 7 after inoculation); pf: pair-fed rats.
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changes in either UCP2 or UCP3 gene expression in skeletal
muscle (Table 2 and Fig. 1). At day 4, both the tumour-bear-
ing animals and the pair-fed ones showed a signi¢cant in-
crease (4.7- and 6.7-fold, respectively) in UCP3 gene expres-
sion while no changes were observed in UCP2. At day 7, both
UCP2 and UCP3 mRNAs were increased in the tumour-bear-
ing group (1.9-fold) while the increase was considerably higher
in the pair-fed group (2.8-fold for UCP2 and 8-fold for
UCP3). From these results it can be concluded that the acti-
vation of UCP2 and UCP3 gene expression at late stages of
tumour growth is basically a consequence of the anorectic
state. However, the signi¢cantly higher UCP3 mRNA levels
found in the pair-fed animals at day 7 (in relation with the
tumour-bearing animals) suggests the possibility that a tu-
mour-induced circulating factor may in£uence skeletal muscle
UCP3 mRNA levels. This gene is abundantly expressed in
skeletal muscle [5], its presence having been detected only in
BAT of rodents [3]. The regulation of its expression is still
poorly known, it is not a¡ected by cold acclimation [5]
although it is increased following thyroid hormone treatment
[25]; starvation increases UCP3 mRNA levels in skeletal
muscle while it decreases them in BAT [26]. UCP3 expression
is also decreased in the soleus muscle of obese Zucker rats [9]
suggesting that it could possibly have a role in obesity.
Heat production in BAT, an important site of non-shiver-
ing thermogenesis in rodents [27], has been for a long time
associated with the UCP1, a mitochondrial protein carrying
the stimulation of heat production resulting from uncoupling
respiration from ATP synthesis. The recent discovery of new
members (UCP2 and UCP3) of the mammalian mitochondrial
uncoupling proteins has resulted in a considerable amount of
information to elucidate the role of these proteins in patho-
physiological conditions. Information concerning the regula-
tion of their mRNA levels is still in an early stage. Starvation
results in an important increase in UCP2 gene expression in
skeletal muscle while it does not in£uence in BAT [8]. Cold
exposure also results in an increase in UCP2 gene expression
in skeletal muscle and BAT [8]. Interestingly, UCP2 levels are
upregulated in WAT in response to fat feeding, suggesting
regulation by diet [1]. We have recently observed that TNF
administration results in an increased skeletal muscle gene
expression of UCP2 without a¡ecting UCP3 levels in rats
(S. Busquets et al., unpublished results).
Cancer cachexia is one of the worst e¡ects of malignancy,
accounting for nearly a third of cancer deaths. It is a patho-
logical state characterised by weight loss together with ano-
rexia, weakness, anemia and asthenia. The complications as-
sociated with the appearance of the cachectic syndrome a¡ect
both the physiological and biochemical balance of the patient
and have e¡ects on the e⁄ciency of the anticancer treatment,
resulting in a considerably decreased survival time. At the
metabolic level, cachexia is associated with loss of skeletal
muscle protein together with a depletion of body lipid stores.
The cachectic patient, in addition to having practically no
adipose tissue, is basically subject to an important muscle
wastage manifested as an excessive nitrogen loss. The meta-
bolic changes are partially mediated by alterations in circulat-
ing hormone concentrations (insulin, glucagon and glucocor-
ticoids in particular) and cytokines, as the molecules
responsible for the above referred metabolic derangements.
In addition, during cachexia there is an important energetic
imbalance. An increase in BAT thermogenesis has been de-
scribed both in humans [16] and experimental animals [17].
Therefore, non-shivering thermogenesis due to either BAT
activity or muscle increased thermogenesis (as suggested
here) may be very important factors contributing to the de-
creased energy e⁄ciency found in the cachectic state.
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